[NICE Quality standard] Lung Cancer in adults

NICE | March 2019 | Lung Cancer in adults Quality standard QS17

NICE have updated the quality standard QS17

This quality standard covers diagnosing and managing lung cancer in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

In March 2019, this quality standard was updated to reflect changes to the updated NICE guideline on lung cancer.

Full details are available from NICE 

[NICE guideline] Lung cancer: diagnosis and management [NG122]

NICE | March 2019 | Lung cancer: diagnosis and management NICE guideline 

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up (Source: NICE).

Full details from NICE 

 

NICE: Promising lung cancer treatment (durvalumab) approved for Cancer Drugs Fund

NICE |  March 2019 | Promising lung cancer treatment approved for Cancer Drugs Fund

NICE has unveiled a promising lung cancer treatment has been approved for the Cancer Drugs Fund, as a result of a NICE recommendation. Today NICE has published draft final guidance.

Durvalumab helps the body’s immune system to find and attack cancer cells, by blocking the PD-L1 protein which disguises cancer.

In a clinical trial people taking it went for an average of around 2 years without the disease progressing, versus 6 months for those without. The committee agreed that it was plausible that between 27% and 40% of people taking durvalumab would have 5 years of progression-free survival.

The draft guidance is available from NICE 

Read the full details from NICE 

See also:

NICE Lung cancer: diagnosis and management

University of Newcastle Promising lung cancer treatment available on the NHS

[NICE Technology appraisal guidance] Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

NICE | February 2019 | Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.

Full details from NICE